Dynamics of Parasite Clearance in Cutaneous Leishmaniasis Patients Treated with Miltefosine by Dorlo, Thomas P. C. et al.
Dynamics of Parasite Clearance in Cutaneous
Leishmaniasis Patients Treated with Miltefosine
Thomas P. C. Dorlo
1,2*, Pieter P. A. M. van Thiel
1, Gerard J. Schoone
3, Ymkje Stienstra
1¤, Miche `le van
Vugt
1, Jos H. Beijnen
2, Peter J. de Vries
1
1Division of Infectious Diseases, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands, 2Department of Pharmacy and Pharmacology,
Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Parasitology Unit, KIT Biomedical Research, Royal Tropical Institute, Amsterdam, The
Netherlands
Abstract
Parasite loads were quantified in repeated skin biopsies from lesions of 2 patients with Old-World cutaneous leishmaniasis
(CL) caused by Leishmania major and L. infantum during and after treatment with miltefosine. Miltefosine induced a rapid
therapeutic effect on both infections with an initial decline of parasites of ,1 log/week for the L. major infection. These
observations illustrate the usability of quantifying parasite loads in skin lesions as a pharmacodynamic measure and
quantitative descriptor of drug effect for CL supporting clinical assessment.
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Introduction
Miltefosine is an oral antileishmanial drug widely used in the
management of visceral leishmaniasis (VL) in the Indian subcon-
tinent [1]. There is increasing evidence on the efficacy of miltefosine
in New-World cutaneous leishmaniasis (CL) [2]. In Old-World CL
the applicability of miltefosine is documented in a few reports with
Leishmania major as causative species [3–6]. The miltefosine dosage
regimens used in CL are based on those established in Indian VL
patients and lack a rational background [7].
Treatment can be given to speed up spontaneous healing of CL.
Systemic treatment is indicated in ‘complex’ disease in patients
with multiple lesions (.5), with lesions in cosmetically or
functionally delicate areas, with lesions which are non-responsive
to intralesional treatment or when mucocutaneous leishmaniasis
may develop. Clinical assessment of the progress and healing of
CL lesions remains difficult, certainly in complex CL cases, where
definitive cure from a clinical perspective is determined up to 6
months post-treatment.
Nothing is known about the dose-effect relationship of
miltefosine in CL, mainly because a good quantitative descriptor
of drug effect has not yet been established. In an attempt to
rationalize the treatment of CL and to support the clinical
examination and follow-up, two patients with Old-World CL for
whom systemic miltefosine treatment was indicated were followed-
up by measuring the Leishmania parasite load in repeated skin
biopsies during and after therapy.
Materials and Methods
Two patients with cutaneous leishmaniasis described in this
report both presented to the Unit of Tropical Medicine at the
Academic Medical Center (AMC), Amsterdam, the Netherlands
and were treated with miltefosine at the currently advised maximal
total daily dose of 50 mg three times daily for a total of 28 days
(Paladin Labs Inc, Montreal, Canada). Informed consent was
obtained from both patients concerning the miltefosine treatment,
the procedures described here and publication of the clinical
descriptions and photographs.
In both patients, full thickness skin biopsies with the same
diameter (2 mm) were taken repeatedly with a sterile disposable
biopsy puncher from the active border of the same lesion at
approximately the same location: at the edge of the inflammatory
zone bordering the necrotic ulcer and always adjacent to the scar
of the previous biopsy site. Biopsies were lysed using 950 mL L6-
buffer, prior to extraction of RNA and DNA [8]. Parasite loads
were measured by quantitative reverse-transcriptase real-time
PCR (qRT-PCR) based on the detection of Leishmania 18S
ribosomal RNA, which may allow for the detection of viable
parasites [8]. Leishmania species were identified using the mini-exon
repeat PCR method described by Marfurt et al. [9], with minor
modifications [10]. Miltefosine plasma concentrations were
measured by a validated liquid chromatography-coupled to
tandem mass spectrometry method (LC-MS/MS) [11].
Results
Case Reports
Clinical description – Patient 1. In December 2008, a 53-
year-old woman consulted the AMC, for a second opinion on
treatment for persistent skin ulcers, elsewhere diagnosed as
cutaneous leishmaniasis. Biopsy of one of the ulcers had shown
Leishman-Donovan (LD) bodies, typed by PCR as L. major.
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discontinued after 2.5 weeks.
In the past 5 years, she regularly made identical short visits to
Morocco working as a travel guide. During the last visit, 2 months
before presentation, papules appeared on trunk, face and upper
extremities, which all progressed to ulcers. Until then she had been
in good health apart from a period of treatment for presumed
mixed connective tissue disease many years ago which was not
further documented. On physical examination she was in a good
condition with normal vital parameters and a body weight of
95 kg. A total of 15 ulcers (diameter 1–3 cm) were noted under the
chin, on the eyelid, in the axillary fold, on upper and lower arms
and on the trunk. No lymphadenopathy or other abnormalities
were present. The purulent ulcer on the eyelid was surrounded by
a red edematous swelling and covered by a crust. The high
number of disseminated lesions and the facial involvement
required systemic treatment. She was advised to take oral
miltefosine (50 mg, thrice daily for a total of 28 days), since
standard parenteral antimony treatment is relatively toxic and
cumbersome. Because of secondary bacterial infection of some of
the ulcers with Staphylococcus aureus, oral azithromycine was
prescribed (first day 1500 mg, followed by 6 days 500 mg daily).
On the first day of treatment, she experienced diarrhea, and
thereafter only stomach aches when the miltefosine capsules were
not taken concurrently with food. At the end of treatment, all
lesions were reduced in size and started to re-epithelialize. Seven
weeks after the end of treatment, all lesions had evolved into scars
with complete re-epitheliazation. At 6 months, no recurrence was
seen and no parasites could be detected in a biopsy from a former
lesion by qRT-PCR (Figure 1A).
Clinical description - Patient 2. In June 2008, a 54-year-
old man known with acne, took a 3-week holiday at the Canary
Island of Tenerife and in Northern Spain, during which he
experienced a painful open sunburn on the nose. Two months
later, non-healing papules and exudative crustated erosions
appeared on the nose and chin, which increased in size and
quantity and were surrounded by an erythematous swelling. He
was diagnosed as having rosacae with secondary bacterial infection
and treated with metronidazole and fucidin cream. A biopsy was
taken from the intranasal tissue, because of obstruction of the left
nasal passage. This revealed a non-specific edematous
inflammatory and fibrinous reaction. In combination with the
then present arthralgia of the right knee, Wegener’s disease was
suspected but was consecutively excluded on the basis of serology,
as well as other autoimmune disorders. In January 2009, infiltrated
erythematous swellings had expanded to the upper lip and cheek,
as also small erythematous erosions appeared above the eyebrow
and on the scalp. A biopsy of the chin lesion showed LD bodies.
He was subsequently referred to the AMC for further
management. The skin lesions were still as described above,
while the mucosa of the left side of the nasal septum showed boggy
indurations with purulent secretion. His body weight was 109 kg
(height 180 cm). Hematology and liver function tests were normal.
Author Summary
The clinical evaluation of the ulcerated lesions in
cutaneous leishmaniasis (CL) is both difficult and subjec-
tive. As a result, the evaluation of therapeutic efficacy of
drugs for CL remains complicated. The relationship
between dose and effect of antileishmanial drugs in CL is
unclear and a good quantitative descriptor of drug effect
has not yet been established. This report describes the use
of quantifying the parasite load in repeated full-thickness
skin biopsies from lesions of two patients with extensive
Old-World CL (Leishmania major and L. infantum) who both
were treated with miltefosine to demonstrate the dynam-
ics of parasite clearance within CL lesions. Therapeutic
effect of miltefosine was already noticeable directly after
start of treatment, with a rapid, log-linear decline in
parasite load in the skin biopsies of approximately 1 log/
week for the L. major infection. These observations
illustrate the applicability of quantifying parasite loads as
a pharmacodynamic measure for CL supporting clinical
assessment. The methodology described here might
enable better evaluation and comparison of standard
and new therapeutics in future randomized clinical trials
for CL.
Figure 1. Clinical follow-up of CL lesions. Photographs of two selected lesions in relation to parasite loads in skin biopsies of two CL patients
treated with miltefosine from the start of treatment until end of follow-up: A) L. major infection, B) L. infantum infection. ND=not determined.
doi:10.1371/journal.pntd.0001436.g001
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demonstrated a L. infantum infection. Because of extensive skin
involvement, he was treated systemically with oral miltefosine
(50 mg, thrice daily for a total of 28 days).
During treatment he experienced many episodes of diarrhea
and vomiting, up to four times a day, but these complaints
subsided when miltefosine was taken together with food. Although
the lesions seemed to ameliorate quickly after the start of
treatment, definite cure could only be concluded on follow-up at
7 months after initiation of therapy (Figure 1B).
Laboratory Investigations
The time courses of Leishmania parasite loads in the skin biopsies
quantified with qRT-PCR are shown in Figure 2. The initial
parasite load for L. major at start of treatment was 1.5610
6, while
the first recorded parasite load for L. infantum at day 15 of
treatment was 1.1610
4. At the end of treatment (day 28), skin
biopsies taken from both patients still revealed the presence of
parasite RNA/DNA as measured by qRT-PCR: 104 and 34
parasites per skin biopsy in the lesions of the L. major and L.
infantum infection, respectively. The lesion of Patient 1 (L. major)
was parasite-free after 50 days after start of treatment with a rapid
parasite clearance rate of ,1 log/week and remained parasite-free
during follow-up examinations. The initial parasite clearance rate
for Patient 2 (L. infantum) between day 15 and 22 of treatment
appeared to be lower (,0.5 log/week) compared to the L. major
infection, although on average in the last two weeks of treatment
(day 15–29) a similar clearance rate of ,1 log/week was observed
in the two infections. Patient 2, however, had a slight upsurge of
parasites on day 50 after start of treatment, despite clinical
improvement of the lesions. Unfortunately, no skin biopsy of
Patient 2 was available from the follow-up period. Miltefosine kept
accumulating until the end of treatment and plasma trough
concentrations had increased on day 28 (last day of treatment) to
38 mg/mL and 29 mg/mL for Patient 1 and Patient 2, respectively
(Figure 2).
Figure 2. Leishmania parasite loads in skin biopsies from lesions of two CL patients treated with oral miltefosine. Miltefosine was given
(50 mg thrice daily) for a total of 28 days. Miltefosine trough plasma concentrations (ng/mL) are indicated by the colored filled areas. The Leishmania
qRT-PCR values of the skin biopsies (parasites/sample) are indicated by colored lines and dots. The green line, circles and filled area represent Patient
1( L. major), while the blue line, squares and filled area represent Patient 2 (L. infantum).
doi:10.1371/journal.pntd.0001436.g002
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This report describes two patients with extensive Old-World
CL: one with L. major infection which suggested dissemination or at
least multiple inoculations and the other with L. infantum infection
of facial skin with collateral swelling of the nasal mucosa. Both
patients were treated with miltefosine and both showed a parallel
log-linear decline of the parasite load in skin biopsies.
The described cases of Old-World CL originated from
Northern Africa and the Mediterranean Basin caused by L. major
and L. infantum, respectively. L. infantum has been described as a
sporadic cause of CL [12–14]. To our knowledge, this case is the
first reported L. infantum-related CL primarily treated with
miltefosine.
The initial parasite load in the skin lesions was high but probably
in the same order of magnitude for both patients (parasite load on
day 0 was missing for the L. infantum infected patient). The repeated
skin biopsies showed a rapid log-linear decline after start of
miltefosine treatment, comparable to the decline rate of parasites in
the blood of a previously miltefosine-treated VL patient [15]. The
reproducible nature of the results was not completely expected,
since we had anticipated a greater variability of parasite density
among the repeated biopsies. This suggests that the parasite density
is rather homogenously spread in the inflammatory zone that
surrounds the necrotic ulcer and that the depth of the biopsy does
not require calibration, as long as the diameter of the punch hole is
calibrated and includes the full-thickness skin, since parasites
accumulate in the upper layer of the dermis.
Therapeutic effect of miltefosine was thus already noticeable
directly after start of treatment, although miltefosine-levels had not
reached steady-state yet. Surprisingly, at the end of treatment (day
28), the examined skin biopsies still revealed the presence of
Leishmania parasites in the lesions of both patients, indicating that
complete elimination of the parasites in the lesion does not occur
within the period of drug administration. After an initial decrease
of the parasite load of L. infantum, this slightly increased again on
day 50, possibly indicating a slower parasite clearance rate in the
lesion of this patient. This may also have been caused by
variability in parasite densities among the biopsy sites. Unfortu-
nately, no further biopsies were taken to confirm complete parasite
clearance from the lesion. Old-World CL is a slow healing
condition of which clinical evaluation can pose difficulties in the
first 3 months and is also known to be self-healing. The purpose of
treatment of CL is to speed up spontaneous cure. Here we
illustrate that parasite clearance rates from skin lesions, which can
be assessed with qRT-PCR, can be used as a pharmacodynamic
measure or ‘biomarker’ in future randomized clinical trials on CL.
Miltefosine has an extremely long terminal half-life of over 30
days, resulting in high plasma concentrations of miltefosine for a
prolonged period of time after ending the 28-day therapy [7].
Whether the continued parasite clearance after discontinuation of
drug administration is due to long-time residence of miltefosine
concentrations after end of therapy, due to induced immunological
response prompted by the therapy or rather natural evolution, is
unknown. It is important to note that CL can be caused by a wide
variety of Leishmania species and a high variability in sensitivity to
miltefosine has previously been shown in vitro between these
different species [16], however various host-related factors make it
difficult to extrapolate these observations to the in vivo sensitivity of
the parasite. The most commonly seen side-effects of miltefosine,
mild to moderate vomiting and diarrhea, are probably related to
drug-intake and not to drug plasma concentrations. Concurrent
intake of a fatty meal largely reduced gastro-intestinal complaints
in both patients.
In conclusion, a rapid therapeutic effect was observed in two
patients with respectively L. major- and L. infantum-related CL after
initiation of miltefosine treatment. Repeated quantifications of the
parasite load in skin biopsies showed a rapid, log-linear, decline of
approximately 1 log/week in the L. major-related CL and lesions
were free of parasites 50 days after start of miltefosine treatment.
The L. infantum-related CL seemed to respond more slowly,
possibly due to mucosal involvement, but definite cure could
eventually be determined at 7 months follow-up. To establish the
role of miltefosine in the treatment of Old-World CL, more and
better designed randomized controlled clinical trials employing
pharmacokinetics and pharmacodynamics are needed.
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